Obesity remains a growing global health challenge with rising prevalence, increasing incidence, and substantial economic burden. Although multiple therapeutic approaches are available, care delivery often remains fragmented, and transparency regarding outcome reporting is limited. Hybrid care models that integrate digital tools with in-clinic visits have been proposed as a patient-centered strategy, yet standardized reporting frameworks are not consistently applied. In a retrospective study published in Diabetes Technology and Obesity Medicine, outcomes of semaglutide and tirzepatide were evaluated within a 6-month hybrid obesity care model using the International Consortium for Health Outcomes Measurement (ICHOM) Obesity standard set.

The study included 528 adults prescribed either semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, or tirzepatide, a dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, alongside behavioral monitoring and virtual engagement. Outcomes were extracted from medical records at baseline, 3 months, and 6 months and analyzed using mixed models for repeated measures. Subgroup analyses by dosage bands were conducted using the Kruskal-Wallis test.

Both treatment groups demonstrated significant improvements in weight, BMI, waist circumference, fat mass, and glycemic control. At 6 months, greater average reductions were observed in the tirzepatide group compared with the semaglutide group for weight (13.15 kg vs 9.54 kg), waist circumference (11.34 cm vs 7.24 cm), and HbA1c (0.33% vs 0.23%).

In this retrospective hybrid-care cohort, both therapies were associated with clinically meaningful improvements over 6 months, with larger average reductions observed in the tirzepatide group. The application of the ICHOM Obesity standard set enabled standardized outcome reporting, and further research is needed to assess long-term outcomes and cost-effectiveness.